These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 18644253)
1. Targeting Hsp90: small-molecule inhibitors and their clinical development. Taldone T; Gozman A; Maharaj R; Chiosis G Curr Opin Pharmacol; 2008 Aug; 8(4):370-4. PubMed ID: 18644253 [TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114 [TBL] [Abstract][Full Text] [Related]
3. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351 [TBL] [Abstract][Full Text] [Related]
4. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276 [TBL] [Abstract][Full Text] [Related]
5. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565 [TBL] [Abstract][Full Text] [Related]
6. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Stravopodis DJ; Margaritis LH; Voutsinas GE Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746 [TBL] [Abstract][Full Text] [Related]
8. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Kim T; Keum G; Pae AN Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970 [TBL] [Abstract][Full Text] [Related]
9. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671 [TBL] [Abstract][Full Text] [Related]
10. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956 [TBL] [Abstract][Full Text] [Related]
11. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors. Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192 [TBL] [Abstract][Full Text] [Related]
13. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance. Zhang H; Neely L; Lundgren K; Yang YC; Lough R; Timple N; Burrows F Int J Cancer; 2010 Mar; 126(5):1226-34. PubMed ID: 19676042 [TBL] [Abstract][Full Text] [Related]
14. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Abramson JS; Chen W; Juszczynski P; Takahashi H; Neuberg D; Kutok JL; Takeyama K; Shipp MA Br J Haematol; 2009 Feb; 144(3):358-66. PubMed ID: 19036086 [TBL] [Abstract][Full Text] [Related]
15. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors. Bhat R; Tummalapalli SR; Rotella DP J Med Chem; 2014 Nov; 57(21):8718-28. PubMed ID: 25141341 [TBL] [Abstract][Full Text] [Related]
16. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202 [TBL] [Abstract][Full Text] [Related]
17. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595 [TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. McCollum AK; TenEyck CJ; Stensgard B; Morlan BW; Ballman KV; Jenkins RB; Toft DO; Erlichman C Cancer Res; 2008 Sep; 68(18):7419-27. PubMed ID: 18794130 [TBL] [Abstract][Full Text] [Related]
19. Purine-scaffold Hsp90 inhibitors. Chiosis G; Tao H IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299 [TBL] [Abstract][Full Text] [Related]
20. Medicinal chemistry of Hsp90 inhibitors. Drysdale MJ; Brough PA Curr Top Med Chem; 2008; 8(10):859-68. PubMed ID: 18673171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]